Utah Medical Products, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9174881089
USD
55.99
1.11 (2.02%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Utah Medical Products, Inc. stock-summary
stock-summary
Utah Medical Products, Inc.
Pharmaceuticals & Biotechnology
Utah Medical Products, Inc. (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company's product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts. UTMD markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit, the labor and delivery department and the women's health center in hospitals, as well as products sold to outpatient clinics and physician's offices.
Company Coordinates stock-summary
Company Details
7043 S Cottonwood St , MIDVALE UT : 84047-1048
stock-summary
Tel: 1 801 5661200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 50 Schemes (37.83%)

Foreign Institutions

Held by 34 Foreign Institutions (3.66%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kevin Cornwell
Chairman of the Board, President, Chief Executive Officer and Secretary
Mr. Ernst Hoyer
Lead Independent Director
Mr. Paul Richins
Director
Dr. James Beeson
Independent Director
Dr. Barbara Payne
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 203 Million (Micro Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

162.65%

stock-summary
Debt Equity

-0.70

stock-summary
Return on Equity

10.68%

stock-summary
Price to Book

1.73